1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with losartan in 2 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 7,231 | 1,245 | 2,118 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | losartan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.01 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
| Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beilin, LJ; Croft, KD; Proudfoot, JM; Puddey, IB | 1 |
| Kumova, TA; medvedev, iN; Simonenko, VB | 1 |
1 trial(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and losartan
| Article | Year |
|---|---|
[Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hypertension; Losartan; Male; Metabolic Syndrome; Platelet Activating Factor | 2008 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and losartan
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Binding Sites; Binding, Competitive; Biphenyl Compounds; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Irbesartan; Lipoproteins, LDL; Losartan; Monocytes; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Tetrazoles | 2003 |